1月5日，市委书记范波调研我市外资企业发展工作。他强调，要深入学习贯彻党的二十届四中全会精神和习近平总书记会见国际工商界代表时的重要讲话 精神，认真落实党中央、国务院决策部署及省委、省政府工作要求，突出创新引领，强化开放赋能，打造一流营商环境，不断增创高水平开放新优势，为 苏州高质量发展提供有力支撑。 在博世新能源汽车核心部件及自动驾驶研发制造基地，范波详细了解核心部件研发、智能制造流程。苏州融媒记者 倪黎祥/摄 在博世新能源汽车核心部件及自动驾驶研发制造基地，范波详细了解核心部件研发、智能制造流程，对企业多次投资加码苏州表示赞赏。他希望企业坚定 发展信心，推动更多前沿技术和高端项目落地苏州。来到三星电子（苏州）半导体有限公司，范波参观企业展厅，听取生产运营情况介绍，鼓励企业提升 先进制造能级，不断增强全球市场竞争力。 在礼来苏州制药有限公司，范波询问产品研发、质量管控和市场拓展情况。苏州融媒记者 倪黎祥/摄 在强生（苏州）医疗器材有限公司、礼来苏州制药有限公司，范波深入生产车间、实验室，询问产品研发、质量管控和市场拓展情况。他指出，苏州正深 入推进生物医药全产业链开放创新，这为包括强生、礼来在内的广大企业带 ...

证券日报网讯 1月5日，奕瑞科技在互动平台回答投资者提问时表示，截至9月30日，公司普通股股东户 数为8011户。 ...

Core Viewpoints - The company is a leading player in the domestic neurointervention sector and is actively expanding into brain-computer interface (BCI) business. By 2026, the company expects rapid revenue growth driven by the commercialization of newly approved innovative products such as the spring coil embolization assist stent and large-caliber suction catheters, along with a self-expanding intracranial drug stent expected to be approved by late 2026 or early 2027. Profit growth is anticipated to outpace revenue growth due to improved operational efficiency [1][4][5] Group 1: Company Developments - The company announced a plan to issue 1 million domestic shares at a 1.10% discount to raise approximately HKD 43.25 million, with the subscription price set at HKD 45.00 per share [1] - The company's vice president and CFO, Zhang Han, will increase his shareholding to 2.54% post-transaction, which is expected to enhance the company's cash reserves for investments and acquisitions in the medical device sector [2] - The company has initiated its A-share IPO plan, which is expected to improve liquidity in the capital market and accelerate its global commercialization efforts [2] Group 2: Product and R&D Progress - The company's BCI project has been selected for the national "reveal the list" initiative, which is expected to expedite clinical trials and development processes, helping to close the gap with leading global products in the BCI field [3] - The company has made significant progress in product development, with the blood flow-directed mesh stent approved for market launch in the first half of 2025, and a self-expanding drug stent for intracranial stenosis expected to complete clinical trials by mid-2026 [4][5] - The company reported a revenue of CNY 186 million in the first half of 2025, a year-on-year increase of 44.4%, and achieved a net profit of CNY 50.94 million, marking a turnaround from losses [5] Group 3: Financial Performance and Projections - The company expects revenues of CNY 402 million, CNY 538 million, and CNY 717 million for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 44.68%, 33.83%, and 33.29% [6] - Projected net profits for the same years are CNY 70 million, CNY 102 million, and CNY 155 million, with growth rates of 617.17%, 44.80%, and 52.39% [6]

Investment Rating - The investment rating for the company is "Buy" [8] Core Insights - The company is expected to maintain high growth due to the expansion of its OLED microdisplay backplane business through a capital increase and introduction of strategic investors [3] - The company reported strong performance in the first three quarters of 2025, with revenue of 1.549 billion yuan, a year-on-year increase of 14.22%, and a net profit of 471 million yuan, up 20.61% [4] - The company is increasing its R&D investment to accelerate product innovation, with key products expected to launch in 2026, which will enhance its competitive edge [5] - Revenue projections for 2025-2027 are 2.32 billion yuan, 2.90 billion yuan, and 3.73 billion yuan respectively, with net profits of 629 million yuan, 838 million yuan, and 1.028 billion yuan [6] Company Overview - The latest closing price of the company's stock is 101.11 yuan, with a total market capitalization of 21.4 billion yuan [2] - The company has a total share capital of 211 million shares, with 200 million shares in circulation [2] - The company has a debt-to-asset ratio of 48.8% and a price-to-earnings ratio of 31.02 [2]

有投资者在互动平台向科华生物提问："你好，贵司在互联网医疗的发展几乎为0，迈，九安却有自己的 淘宝店，圣湘也有合作平台，现抖音集团也涉足医疗服务，并即将开设医院，请问贵司各博士教授有考 虑跟上时代的步伐吗？" 针对上述提问，科华生物回应称："尊敬的投资者，您好！同行业上市公司在产品发展战略、产品结 构、业务类别、技术路径等方面存在区别，每家公司主营产品各不相同，侧重的技术路线也各有特点和 差别，公司产品的配套市场也有区别。公司会密切关注行业发展趋势和市场需求，结合公司实际业务需 要和发展战略，制定业务规划，积极把握相关业务机会。感谢您的关注！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

Core Viewpoint - The company aims to break the dominance of imported products in the high-end domestic contact lens market by leveraging its core technological capabilities in ophthalmic optics, materials, and precision manufacturing [2] Company Summary - The company has developed products that meet international standards, utilizing its comprehensive R&D capabilities and large-scale production capacity [2] - It has achieved full control over the technology across all stages, from core materials and key molds to automated production equipment [2] - The company is actively enhancing its brand and channel systems to strengthen its market position [2] Industry Summary - The industry has experienced significant changes in supply and demand dynamics, leading to increased market competition since last year [2] - Despite current business progress falling short of expectations, the domestic market still holds growth potential [2] - The company is focused on continuously optimizing processes, iterating products, improving channels, and strengthening brand management to enhance overall competitiveness [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [13]. Core Insights - The company, 山外山, holds a leading market share in blood dialysis equipment, with a November 2025 market share of 18.75%, surpassing competitors like 费森尤斯 and 贝朗 [3]. - The company has demonstrated robust revenue growth, with a 39.79% increase in revenue to 584 million yuan and a 68.68% increase in net profit to 104 million yuan for the first three quarters of 2025 [4]. - The company is expected to see a significant increase in the contribution of consumables to its overall performance, driven by its leading position in the blood purification equipment market and a focus on enhancing consumable sales [5]. - Revenue projections for 2025-2027 are estimated at 760 million yuan, 950 million yuan, and 1.2 billion yuan, with corresponding net profits of 151 million yuan, 191 million yuan, and 238 million yuan, reflecting a strong growth trajectory [6]. Company Overview - The latest closing price of the company's stock is 14.97 yuan, with a total market capitalization of 4.8 billion yuan [2]. - The company has a total share capital of 320 million shares, with a price-to-earnings ratio of 67.52 [2]. - The company’s largest shareholder is 高光勇 [2].

Core Viewpoint - The company is progressing with its "X-ray vacuum device and comprehensive solution construction project" as planned, with ongoing product development and customer integration [2] Group 1: Product Development - The company has completed the research and development of several types of X-ray tubes, including micro-focus tubes, transmission target tubes, dental intraoral tubes, DR tubes, C-arm tubes, and some CT tubes [2] - Micro-focus tubes, transmission target tubes, dental intraoral tubes, and CBCT tubes have already entered mass production [2] - The C-arm tube has completed registration and is transitioning to production, while some DR tubes and CT tubes are expected to start registration in the first quarter of 2026 [2] Group 2: Business Outlook - As the company’s tube products gradually complete registration and commercialization, along with the expansion of its comprehensive solution business, it is anticipated that future orders and self-use quantities will gradually increase [2]

证券日报网讯 01月5日，鱼跃医疗在互动平台回答投资者提问时表示，公司不同款型的呼吸机产品可满 足多类用户群体的需求，目前公司推出了便携式小型呼吸机，产品详情请咨询客服热线400-828-7768。 （编辑 任世碧） ...

（文章来源：证券日报） 证券日报网讯 1月5日，东富龙在互动平台回答投资者提问时表示，公司积极立足"提质增效"的主题， 发挥产品创新的技术优势，提升公司产品结合前沿技术的能力，进一步打造产品的差异化竞争优势，做 好为客户提供广泛服务的能力，为赢取优质订单奠定扎实基础，努力提升公司的盈利能力。 ...